This from the NY times via the PharmaGossip blog bemoaning the fact that the genome map has yet to result in the revolution of new drugs that was predicted 10 years ago when the map was announced.
Basically, this shows the amount of time it takes to research and bring a new therapeutic to market- averaging slightly more than 15 years. It also shows the relative impatience of the public/press when it comes to this process - and perhaps a misunderstanding of its complexitiy. This may also reflect the seemingly greater difficulty in getting through the FDA.
Pharma executives at companies like Genentech, Merck, and BMS indicate that the genome project has resulted in new work practices in pharmaceutical R&D that are effecting how new drugs are being brought forward. Many of these are just getting to late stage clinicals before reaching the market- several in the cancer arena.
But it appears the biggest effect of the genome project is that more targets are now available to pharma investigators. However, it still takes 10-15 years to design a drug versus the selected targets and bring the product to market. In that respect, the genome map has not helped speed the path to commercialization.
Posted by Bruce Lehr June 16th 2010.